These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 33904154)

  • 21. Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies.
    Artigas F; Celada P; Bortolozzi A
    Eur Neuropsychopharmacol; 2018 Apr; 28(4):457-482. PubMed ID: 29525411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders.
    Ghasemi M; Phillips C; Fahimi A; McNerney MW; Salehi A
    Neurosci Biobehav Rev; 2017 Sep; 80():555-572. PubMed ID: 28711661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Glutamatergic Treatments for Severe Mood Disorders.
    Park M; Niciu MJ; Zarate CA
    Curr Behav Neurosci Rep; 2015 Dec; 2(4):198-208. PubMed ID: 26824031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.
    Peyrovian B; Rosenblat JD; Pan Z; Iacobucci M; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():387-404. PubMed ID: 30738126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Convergent Mechanisms Underlying Rapid Antidepressant Action.
    Zanos P; Thompson SM; Duman RS; Zarate CA; Gould TD
    CNS Drugs; 2018 Mar; 32(3):197-227. PubMed ID: 29516301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glutamate-based antidepressants: preclinical psychopharmacology.
    Pilc A; Wierońska JM; Skolnick P
    Biol Psychiatry; 2013 Jun; 73(12):1125-32. PubMed ID: 23453290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
    Halaris A; Cook J
    Adv Exp Med Biol; 2023; 1411():487-512. PubMed ID: 36949323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond monoamines: glutamatergic function in mood disorders.
    Kugaya A; Sanacora G
    CNS Spectr; 2005 Oct; 10(10):808-19. PubMed ID: 16400244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets.
    Małgorzata P; Paweł K; Iwona ML; Brzostek T; Andrzej P
    Expert Opin Ther Targets; 2020 Dec; 24(12):1187-1209. PubMed ID: 33138678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glutamatergic conception of mood disorders].
    Permoda-Osip A; Rybakowski J
    Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials.
    Majeed A; Xiong J; Teopiz KM; Ng J; Ho R; Rosenblat JD; Phan L; Cao B; McIntyre RS
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):63-74. PubMed ID: 33682569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.